Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

HALOPERIDOL

All products: general benefit

Other products in the same Health Canada class (N05A) — coverage varies; not interchangeable

  • Aripiprazole (Abilify Asimtufii): general benefit
  • Asenapine (Saphris): general benefit
  • Brexpiprazole (Rexulti): general benefit
  • Cariprazine (Vraylar): general benefit
  • Chlorpromazine (Teva-Chlorpromazine): general benefit, Not a benefit
  • Flupentixol decanoate (Fluanxol Depot): general benefit

18 more in the class list below

Teva-Haloperidol · DIN 00768820 · 20mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.Discontinued 2021-07-30 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Haloperidol · DIN 00768820 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2021-07-30 · brand TEVA-HALOPERIDOL · ATC N05AD01 HALOPERIDOL · form Tablet · route Oral · ingredients HALOPERIDOL 20 MG · company Peptech animal health pty ltd. · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Haloperidol: Formulary list price $1.3047/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3047 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8477 · Verify on the e-Formulary ↗ (DIN 00768820)

Source record
DIN 00768820: Teva-Haloperidol Raw flags: sec3=Y Item: 281608112; group id 492; item number 1264; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $1.3047; ministry $1.3047 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00768820 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8477
Interchangeable products
Haldol · DIN 00499579 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

LURASIDONE HYDROCHLORIDE

· 38 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4), General benefit (33), Listed, not a benefit (1) · strengths: 20mg, 40mg, 60mg, 80mg, 120mg · Tab

OLANZAPINE

· 116 products · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) · strengths: 5mg, 10mg, 15mg, 20mg, 2.5mg, 7.5mg · Rapid Dissolve Tab, Tab

PALIPERIDONE

· 3 products · General benefit · strengths: 3mg, 6mg, 9mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USES TEVA-HALOPERIDOL (haloperidol) is indicated in the management of manifestations of acute and chronic psychosis, including schizophrenia and manic states. It may also be of value in the management of aggressive and agitated behavior in patients with chronic brain syndrome and mental retardation and in the symptomatic control of Gilles de la Tourette’s syndrome. https://pdf.hres.ca/dpd_pm/00036413.PDF PM date: August 26, 2016 Source product: TEVA-HALOPERIDOL; DIN 00363650; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.